
ROZEBALAMIN® Injection for ALS Wins 2024 Good Design Award for Lightproof Vial Packaging
Eisai’s Rozebalamin® for Injection 25 mg Wins Good Design Award 2024 for Light-Proof Vial Packaging Eisai Co., Ltd. (Tokyo, CEO: Haruo Naito) announced that its amyotrophic lateral sclerosis (ALS) treatment,…












